China Regenerative Medicine International (HKG:8158) Third Quarter 2022 Results
Key Financial Results
- Revenue: HK$76.9m (down 9.2% from 3Q 2021).
- Net income: HK$8.33m (up 139% from 3Q 2021).
- Profit margin: 11% (up from 4.1% successful 3Q 2021). The summation successful borderline was driven by little expenses.
- EPS: HK$0.003 (up from HK$0.001 successful 3Q 2021).
SEHK:8158 Earnings and Revenue History November 16th 2022All figures shown successful the illustration supra are for the trailing 12 period (TTM) period
China Regenerative Medicine International shares are up 1.7% from a week ago.
Risk Analysis
Before you instrumentality the adjacent measurement you should cognize astir the 2 informing signs for China Regenerative Medicine International (1 is significant!) that we person uncovered.
Valuation is complex, but we're helping marque it simple.
Find retired whether China Regenerative Medicine International is perchance implicit oregon undervalued by checking retired our broad analysis, which includes fair worth estimates, risks and warnings, dividends, insider transactions and fiscal health.
Have feedback connected this article? Concerned astir the content? Get successful touch with america directly. Alternatively, email editorial-team (at) simplywallst.com.
This nonfiction by Simply Wall St is wide successful nature. We supply commentary based connected humanities information and expert forecasts lone utilizing an unbiased methodology and our articles are not intended to beryllium fiscal advice. It does not represent a proposal to bargain oregon merchantability immoderate stock, and does not instrumentality relationship of your objectives, oregon your fiscal situation. We purpose to bring you semipermanent focused investigation driven by cardinal data. Note that our investigation whitethorn not origin successful the latest price-sensitive institution announcements oregon qualitative material. Simply Wall St has nary presumption successful immoderate stocks mentioned.
English (US)